Beijing GoBroad Boren Hospital| Expert Perspective | Director Hu Kai: What You Need to Know About CAR-T Therapy for Malignant Lymphoma & Multiple Myeloma
Updated: Oct 18
The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients.

For patients with Diffuse Large B-Cell Lymphoma (DLBCL) resistant to the R-CHOP regimen (rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone), long-term survival prospects remain poor regardless of clinical stage or genetic risk stratification. Novel therapies are urgently needed to improve long-term outcomes for these relapsed/refractory patients.
1. Clinical Trials of CAR-T for R/R DLBCL
CAR-T therapy has achieved remarkable success in relapsed/refractory acute lymphoblastic leukemia, and delivers promising efficacy for DLBCL. Key global landmark trials are summarized below:
ZUMA Trial
The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.
JULIET Trial
A global multicenter trial adopting CAR-T with 4-1BB costimulatory domain, which demonstrated milder adverse reactions compared to CD28-based constructs.
Outstanding challenges remain for CAR-T in R/R DLBCL: optimal timing of CAR-T intervention, higher complete remission (CR) rates, long-term disease control post-remission, and standardized clinical management of CRS toxicity.
2. Clinical Outcomes of CAR-T for Lymphoma & Myeloma at Our Adult Lymphoma Department
Our team conducts multiple immunotherapy programs: CD19 CAR-T for R/R B-cell malignancies, sequential CD19/CD22 CAR-T for R/R DLBCL, and BCMA CAR-T for relapsed/refractory multiple myeloma.
Patient Profile
Treated patients include DLBCL, Burkitt lymphoma, follicular lymphoma and multiple myeloma, mostly stage III/IV with heavily pretreated histories (average 10 chemotherapy cycles). Many relapsed after autologous stem cell transplantation or prior CAR-T therapy elsewhere, presenting progressive disease at admission with high clinical difficulty.
Therapeutic Efficacy
Early CR rate reaches 64%, overall response rate ~70%. Multiple myeloma achieves superior outcomes; heavily pretreated, rapidly progressive DLBCL and Burkitt lymphoma show suboptimal responses.
Safety Profile
Overall CRS incidence: ~80%; 70% grade I–II, only 13.20% severe grade III–IV. Median CRS onset day 5 (range 1–11).
Representative Case Reports
Case 1: Diffuse Large B-Cell Lymphoma
Non-germinal center DLBCL, stage IVB. The patient achieved PR after 4 cycles of R-CHOP, then complete remission after R2-CHOP and autologous stem cell transplant, maintained with lenalidomide consolidation. Three months prior to admission, recurrent abdominal mass (6.7cm×8.4cm×7.1cm), bilateral pulmonary and left renal nodules developed. GDP chemotherapy failed to control progression, accompanied by fever, emaciation, jaundice, partial intestinal obstruction and gastrointestinal hemorrhage.
Direct CAR-T infusion carried high risks of massive gastrointestinal bleeding and severe pulmonary CRS. We first controlled hemorrhage and obstruction with debulking conditioning chemotherapy, then administered murine CD19 CAR-T with standardized CRS supportive care. All symptoms resolved post-infusion; PET-CT at day 60 confirmed full clearance of primary lesions.
Case 2: Multiple Myeloma
Elderly male with 10-year history of IgG-Kappa multiple myeloma. Attained CR after PAD/VAD chemotherapy and autologous transplantation, maintained with lenalidomide plus 8 cycles of CIK cell therapy. Disease progressed later despite multiple lines of treatment (PCD, PRD, chidamide, carfilzomib, anti-CD38 monoclonal antibody, pomalidomide).
Lumbar extramedullary plasmacytoma developed, complicated by pulmonary fungal infection and coronary stent implantation. Admission tests revealed 52% abnormal plasma cells in bone marrow, 14.85% BCMA-positive plasma cells, plus TP53/KRAS mutations.
We administered reduced-dose conditioning chemotherapy and split BCMA CAR-T infusion on day 1 and day 14 to mitigate toxicity. Only grade 1 fever occurred as CRS. At day 30 and 46 post-infusion, IgG levels normalized, bone marrow plasma cells turned negative, and PET-CT showed full resolution of extramedullary lesions.
Summary & Future Research Directions
Individualized debulking regimens for patients with high tumor burden before CAR-T infusion;
Combined and sequential multi-target CAR-T strategies to enhance efficacy;
Standardized minimal residual disease (MRD) monitoring to guide post-remission maintenance therapy.
Planning treatment in China?
MedTourChina helps international patients reach hospitals such as leading Chinese hospitals. Send your medical reports and our coordinators will compare specialists, treatment timelines and costs for you — at no charge.



Comments